RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
CAMBRIDGE, Md., Sept. 18, 2017 -- ConverGene is pleased to announce that it has entered into a collaboration with The University of Texas MD Anderson Cancer Center (“MD Anderson”) to characterize ConverGene’s first-in-class dual inhibitor of BET bromodomains and dopamine receptor 2, in ovarian carcinoma. Work will be done under the guidance of Dr. Sherry Wu in the laboratory of Dr. Anil Sood. The program will advance in 2 distinct phases. First the unique mechanism of action of the ConverGene lead compound will be assessed in vitro then clinically relevant activity will be determined utilizing in vivo model systems developed in the Sood lab.
Dr. Jeff Strovel, PhD, President and CEO of ConverGene, commented, “We are very excited to kickoff this study with MD Anderson. Our first-in-class cancer drug candidates will be evaluated by a world-class team working with a renown leader in the field of gynecological cancer.”
Dr. Anil Sood is Professor and Vice Chair for Translational Research in the Departments of Gynecologic Oncology and Cancer Biology at the MD Anderson Cancer Center. He is also Director of the multi-disciplinary Blanton-Davis Ovarian Cancer Research Program. Dr. Sood co-leads the Ovarian Cancer Moonshot Program.
NOTES TO EDITORS
About ConverGene
ConverGene (www.convergenepharma.com) is a small molecule discovery company leveraging rational drug design. Our mission is to develop therapeutics with novel mechanisms of action for patients with limited or no treatment options.
Our first-in-class lead drug program, CVG-101, contains small molecule inhibitors formulated for oral administration that are selective against BET proteins. CVG-101 contains multiple clinical candidates that exhibit dual activity, simultaneously inhibiting epigenetic processes within cancer cells as well as D2R which is a driver of proliferation and metastasis in cancer. We predict this drug will gain broad clinical usage due to its dual activity and potential to reduce the development of resistance.
ConverGene believes that its portfolio of intellectual property protects its product candidates and technologies. Opportunities to realize significant early value inflection points are available through strategic licensing of our drug candidates. For additional information on ConverGene, please visit its website at convergenepharma.com.
For more information please contact Dr. Elizabeth Smith, [email protected]
